↓ Skip to main content

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database

Overview of attention for article published in Neuro-Oncology, February 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter
42 X users

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
77 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database
Published in
Neuro-Oncology, February 2018
DOI 10.1093/neuonc/noy017
Pubmed ID
Authors

Deborah T Blumenthal, Minhee Won, Minesh P Mehta, Mark R Gilbert, Paul D Brown, Felix Bokstein, David G Brachman, Maria Werner-Wasik, Grant K Hunter, Egils Valeinis, Kirsten Hopkins, Luis Souhami, Steven P Howard, Frank S Lieberman, Dennis C Shrieve, Merideth M Wendland, Cliff G Robinson, Peixin Zhang, Benjamin W Corn

Abstract

We previously reported the unexpected finding of significantly improved survival for newly-diagnosed glioblastoma patients when radiation therapy (RT) was initiated later (>4 weeks post-op) compared to earlier (≤2 weeks post-op). In that analysis, data were analyzed from 2855 patients from 16 NRG Oncology/RTOG trials conducted prior to the era of concurrent temozolomide (TMZ) with RT. We now report on 1395 newly-diagnosed glioblastoma patients from two studies, treated with RT and concurrent TMZ followed by adjuvant TMZ. Our hypothesis was that concurrent TMZ has a synergistic/radiosensitizing mechanism, making RT timing less significant. Data from patients treated with TMZ-based chemo-radiation from NRG Oncology/RTOG 0525 and 0825 were analyzed. An analysis comparable to our prior study was performed to determine whether there was still an impact on survival by delaying RT. Overall survival (OS) was investigated using the Kaplan-Meier method and Cox proportional hazard model. Early progression (during time of diagnosis to 30 days after RT completion) was analyzed using the Chi-square test. Given the small number of patients who started RT early following surgery, comparisons were made between >4 and ≤4 weeks delay of radiation from time of operation. There was no statistically significant difference in OS (HR=0.93; p-value=0.29; 95% CI: 0.80-1.07) after adjusting for known prognostic factors (RPA and MGMT methylation status). Similarly, the rate of early progression did not differ significantly (p-value=0. 63). We did not observe a significant prognostic influence of delaying radiation when given concurrently with TMZ for newly-diagnosed glioblastoma. The effects of early (1-3 weeks post-operatively) or late (>5 weeks) initiation of radiation tested in our prior study could not be replicated.

X Demographics

X Demographics

The data shown below were collected from the profiles of 42 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 77 100%

Demographic breakdown

Readers by professional status Count As %
Other 9 12%
Student > Bachelor 8 10%
Researcher 7 9%
Student > Doctoral Student 7 9%
Student > Postgraduate 7 9%
Other 13 17%
Unknown 26 34%
Readers by discipline Count As %
Medicine and Dentistry 37 48%
Unspecified 4 5%
Neuroscience 3 4%
Biochemistry, Genetics and Molecular Biology 1 1%
Psychology 1 1%
Other 3 4%
Unknown 28 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2020.
All research outputs
#1,674,028
of 25,706,302 outputs
Outputs from Neuro-Oncology
#235
of 3,565 outputs
Outputs of similar age
#41,213
of 472,632 outputs
Outputs of similar age from Neuro-Oncology
#3
of 85 outputs
Altmetric has tracked 25,706,302 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,565 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 472,632 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.